SHORT REPORT

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

C Langner¹, M Ratschek¹, P Rehak², L Schips³ and R Zigeuner³

¹ Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria
² Department of Surgery, Division of Biomedical Engineering and Computing, Medical University of Graz
³ Department of Urology, Medical University of Graz

Correspondence to:
Correspondence to:
Dr C Langner
Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; cord.langner{at}meduni-graz.at

Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation.

Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique.

Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not.

Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.

Abbreviations: EGFR, epidermal growth factor receptor; RCC, renal cell carcinoma

Keywords: renal cell carcinoma; epidermal growth factor receptor; immunohistochemical evaluation; prognosis; treatment

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Martin, V, Mazzucchelli, L, Frattini, M (2009). An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J. Clin. Pathol. 62: 314-324 [Abstract] [Full Text]  
• Hoffmann, S., Wunderlich, A., Lingelbach, S., Musholt, P. B., Musholt, T. J., von Wasielewski, R., Zielke, A. (2008). Expression and Secretion of Endostatin in Thyroid Cancer. Ann. Surg. Oncol. 15: 3601-3608 [Abstract] [Full Text]  
• Schoffski, P., Dumez, H., Clement, P., Hoeben, A., Prenen, H., Wolter, P., Joniau, S., Roskams, T., Van Poppel, H. (2006). Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17: 1185-1196 [Abstract] [Full Text]